Skip to main content
S&P 5007,676.77+0.70%DOW52,361.58+0.28%NASDAQ26,169.38+0.82%BTC$80,129.00+0.25%ETH$2,324.65+0.23%GOLD$4,027.20-0.28%OIL$101.22-0.53%
Smart Investors Daily
SID Premium
MB

NASDAQ · MBRX

Moleculin Biotech, Inc.

Healthcare · Biotechnology

$7.09

Up+$0.59 (+9.00%)

Updated Oct 27, 2026, 7:49 AM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
6.01M
P/E ratio
-0.18
Dividend yield
0.00%
52-week range
$0.16 – $15.75
Volume
25.46K
Avg. volume
194.99K

Price performance · MBRX

MBRX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

MBRX closed at $7.09 after 21 trading sessions, up 1145.17% for the selected period.

Last close
$7.09
Period change
+1145.17%
Period low
$0.41
Period high
$8.22
Daily close
View OHLC price history
MBRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$6.59$7.25$6.50$7.08525.46K
Oct 23, 2026$6.05$6.59$5.6483$6.5027.67K
Oct 22, 2026$6.13$6.1638$5.46$5.8959.13K
Oct 21, 2026$6.00$6.58$6.00$6.3142K
Oct 20, 2026$5.74$6.4025$5.24$6.19131.77K
Oct 19, 2026$5.60$5.60$4.42$5.3053.31K
Oct 16, 2026$6.20$6.60$5.60$5.60859.42K
Oct 15, 2026$8.40$8.52$7.402$7.40216.8K
Oct 14, 2026$8.798$8.798$8.192$8.2213.75K
Oct 13, 2026$0.424$0.4361$0.4102$0.4352183.47K
Oct 12, 2026$0.45$0.4531$0.41$0.4139173.92K
Oct 9, 2026$0.4199$0.4564$0.4127$0.442342.53K
Oct 8, 2026$0.4371$0.4415$0.4107$0.424268.07K
Oct 7, 2026$0.4579$0.4582$0.431$0.4389433.44K
Oct 6, 2026$0.4878$0.49$0.44$0.4455706.73K
Oct 5, 2026$0.49$0.4902$0.4618$0.4766476.44K
Oct 2, 2026$0.51$0.5149$0.4715$0.4868422.27K
Oct 1, 2026$0.505$0.5188$0.50$0.5038337.13K
Sep 30, 2026$0.5409$0.5498$0.492$0.5004720.15K
Sep 29, 2026$0.573$0.58$0.52$0.52641.66M
Sep 28, 2026$0.60$0.60$0.5401$0.569625.49K

Latest MBRX news

The latest Smart Investors Daily articles mentioning MBRX.

Stock researchCompany · Overview

MBRX research

Overview

Company profile and research snapshot.

Company profile

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$170.00
Implied upside
—
Analysts
9
MBRX recent ratings
DateFirmRatingTarget
Aug 28, 2026HC Wainwright & Co.Buy—
Mar 24, 2026HC Wainwright & Co.Buy—
Dec 11, 2025HC Wainwright & Co.Buy—
Sep 10, 2025HC Wainwright & Co.Buy—
Aug 27, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial

Access the Moleculin CEO Corner here HOUSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer. In this episode of CEO Corner, Moleculin Biotech Chairman and CEO Walter Klemp discusses the progress of the Company’s Phase 2/3 MIRACLE trial evaluating Annamycin in combination with high-dose cytarabine (HiDAC) for

Yahoo · Oct 16, 2026

Moleculin Announces Reverse Stock Split

HOUSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on October 20, 2026, and the Company’s common stock will open for trading on The Nasdaq Capital Market

Yahoo · Oct 7, 2026

Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit

HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New York, NY. Details of the presentation are as follows: Session: Advances in Oncology PanelPresenter: Walter Klemp, Chairman and Chief Executive Officer of Moleculin Date/time: Wednesday, October 14, 2026, from 9:00 - 10:00 a.m. ETLocation: NYY Room at the Hard Rock Hotel NYC Mr. Klemp will discuss Mole

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By